No actionable signal, this is standard new-hire equity compensation for a commercial-stage biotech. Monitor upcoming earnings or pipeline catalysts (revumenib, entinostat) for real share-moving events.
SNDX drugs
SNDX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 2 $21.82entry
- T+1 · 4mo ago +1.19%α +0.32% · $22.08
- T+5 · 4mo ago +13.84%α +12.91% · $24.84
- T+20 · 4mo ago −10.72%α −10.31% · $19.48
- T+60 · 7w ago −16.59%α −20.16% · $18.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Syndax granted 250,700 performance-based stock options to 8 new hires under its 2023 Inducement Plan, with four-year graded vesting. This is routine new-hire inducement equity for a commercial-stage biotech, no material financial impact.
Key Facts
- 250,700 shares of common stock granted as inducement awards to 8 new employees
- Awards are stock options under the 2023 Inducement Plan
- Vesting: 25% at one-year anniversary, then monthly over 36 months (total 4-year vest)
- Grant date: July 1, 2026; vesting commencement date and exercise price not stated
Financial Impact
Routine equity grant, no cash impact; ~0.3% dilution of ~83M basic shares outstanding (not stated, est.)
Risk Factors
- None from this filing, new-hire inducement grants are routine
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320972 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Viewing Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers